FDA, CMS Memorandum Of Understanding Draft Circulating At Staff Level
This article was originally published in The Gray Sheet
Executive Summary
FDA approval timeframes for breakthrough technology could be shortened by leveraging Medicare claims data for postmarket surveillance, according to CMS Chief Medical Officer Sean Tunis, MD